Daniel Rabinowitz, SEC and Chief Legal Officer at Natera, Inc. (NASDAQ: NTRA), executed an open-market sale of 1,745 shares of common stock on March 10, 2026. The shares moved at a price of $204.1327 each, producing gross proceeds of $356,211.
The disposition followed an event the previous day: on March 9, 2026, Rabinowitz was issued 1,745 shares of Natera common stock as Restricted Stock Units (RSUs). According to the filing, those RSUs were fully vested at the time of issuance.
After the March 9 and March 10 transactions, Rabinowitz's direct holdings totaled 233,285 shares of Natera common stock.
Valuation context and market view
The insider sale occurred against a backdrop in which the stock has returned 36% over the last 12 months, even as InvestingPro analysis flags the company as appearing overvalued at current market levels relative to its Fair Value. That juxtaposition - strong share performance but questions around valuation - frames investor interpretation of the transaction.
Company results and analyst responses
Natera reported fourth-quarter 2025 revenue of $666 million, topping the consensus expectation of $590.72 million and representing a 12.66% revenue surprise versus estimates. The company also reported notable test volume growth across its business lines, with particular emphasis on Signatera's clinical test volume.
In response to the quarter, Canaccord Genuity reiterated its Buy rating on Natera shares and kept a $285 price target in place, citing the strong results. Morgan Stanley adjusted its model after the quarter as well, trimming its price target from $265 to $250 while retaining an Overweight rating; that valuation action was grounded in a discounted cash flow analysis that incorporated specific financial metrics.
What this means for investors
The combination of an insider sale immediately following a fully vested RSU issuance, a year-to-date share gain of roughly 36%, an InvestingPro view of potential overvaluation, and mixed analyst target movements creates multiple inputs for investors assessing Natera. The companys quarter-over-quarter operational signals - including rising test volumes in key segments - sit alongside questions about current valuation metrics and model sensitivity reflected in analyst adjustments.
Readers should note the transactions and the reported financial results when evaluating near-term positioning in NTRA equity.